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Abstract
Background: Herbal medicines long have been used in the management of  diabetes mellitus (DM).
Objective: This study was conducted to ascertain if  fenugreek compared with glibenclamide had any impacts on controlling 
blood glucose in patients with uncontrolled type II DM on conventional therapy.
Methods: A total of  12 patients with uncontrolled DM and on metformin were recruited and divided into two groups. Patients 
in group 1 received 2 g fenugreek per day, whereas those in group 2 received glibenclamide 5 mg once daily. The impacts of  
fenugreek on the glycemic control and lipid profile were measured before initiation of  the regimen and then after 12 weeks.
Results: Only 9 of  the 12 study participants completed the study. Fenugreek at 2 g/day caused an insignificant drop in fasting 
blood glucose (P = 0.63), but the fasting insulin level increased significantly (P = 0.04). The ratio of  high- to low-density lipopro-
tein was significantly decreased from before to after treatment (P = 0.006). Fenugreek did not cause any notable adverse impacts 
on hepatic and renal functions throughout the study.
Conclusion: Fenugreek could be used as adjuvant therapy to anti-diabetic drugs to control blood glucose, and further studies 
are needed.
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Introduction
Diabetes mellitus (DM) is a heterogeneous condition 
with features of  altered cell metabolism. 
In 2014, World Health Organization reported that over 
400 million people were diabetic worldwide1. DM is more 
common in developed compared with developing coun-
tries due to nutritional and lifestyle factors2. The incidence 
of  diabetes has been on the rise probably due to lifestyle 
changes that encourage sedentary lifestyles, lack of  exer-
cise, and aging3. Uncontrolled DM increases the risks of  
morbidity and/or mortality from DM complications.
Management of  diabetes usually is complex following its 
complex pathophysiology and devastating complications. 
Patients with diabetes are often put on a treatment plan 
that encompasses health and wellness teaching, nutri-
tional education, as well as encouraging adherence to the 
established therapeutic plan. The guidelines for manage-
ment of  type 2 DM recommended metformin as the first 
line drug when diet and exercise do not work. However, 
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most anti-diabetic drugs are expensive, and some have 
adverse effects. Thus, there is a need for new therapies 
with fewer side effects and better cost-effectiveness. Me-
dicinal plants have been used in attempts to control DM.
Among many plants, Trigonella foenum-graecum (fenugreek) 
has been used traditionally in the management of  blood 
glucose levels in patients with type 2 DM in many Ara-
bic countries4-6. The anti-diabetic effect of  fenugreek has 
been confirmed in patients with diabetes7,8. From the in 
vivo studies, it has been suggested that fenugreek con-
trols blood sugar levels mainly by inhibition of  carbohy-
drate digestion and absorption, and enhancement of  pe-
ripheral insulin action7. Nevertheless, there is not enough 
evidence of  fenugreek’s effect on patient with diabetes. 
Thus, an open-labeled controlled study was conducted on 




This interventional open-label randomized controlled 
allocation concealed trial evaluated the efficacy of  fenu-
greek versus glibenclamide in controlling blood glucose 
levels in patients with uncontrolled diabetes.
Methods
This study included 12 randomly selected patients with 
type 2 DM receiving metformin as per the hospital pro-
tocol. The subjects were recruited from the Department 
of  Medicine in King Abdulaziz University Hospital in 
Jeddah between October 2010 and April 2012. The study 
protocol was approved by the King Abdulaziz University 
Hospital Independent Ethics Committee Center before 
enrollment of  any subject, and informed consent was 
obtained before randomization. The study included 12 
patients with diabetes of  both sexes, aged more than 18 
years. Patients with type 2 DM and a fasting blood glu-
cose (FBG) level greater than or equal to 140 mg/dL of  
blood with no notable complications, hemoglobin A1c 
(HbA1c) levels greater than 7%, and those receiving an 
metformin with a history of  poorly controlled serum glu-
cose were included in the study.
Exclusion criteria were patients who were already on 
sulfonylurea drugs, patients who could not provide in-
formed consent for participation; patients on medica-
tions, such as cortisone, that affect serum glucose levels; 
pregnant and lactating patients; and patients with com-
plications arising from diabetes. Also excluded from the 
study were patients with type 1 DM, patients with mental 
illness, patients treated with insulin therapy, or those with 
other conditions, such as gastrointestinal tract, renal, he-
patic, cardiovascular, and endocrine conditions that could 
affect the absorption and metabolism of  fenugreek.
The candidates were allocated randomly into two groups 
using a computer-generated randomization list. To ensure 
concealment, opaque sealed envelopes were numbered, 
and each contained a card with the allocation information. 
A study nurse was assigned to open envelopes to allocate 
patients into two groups. In group 1, patients received 
2 g fenugreek (Fenugreek; GNC, Pittsburgh, PA, USA) 
spread over the day as 500 mg (one capsule) after break-
fast, 1000 mg (two capsules) after lunch, and 500 mg (one 
capsule) after dinner. This dose is as suggested by GNC 
company for over-the-counter use. The study participants 
were asked to take the capsules post-prandially together 
with their medications. In group 2, patients received 5 mg 
glibenclamide once daily (OD) (Daonil; Aventis Pharma, 
Midrand, South Africa)9. Both groups were asked to con-
tinue on their metformin regimen and take fenugreek/ 
glibenclamide as an adjuvant to metformin.
Following randomization, the subjects were scheduled to 
visit the clinic at 0 and 12 weeks from the commence-
ment of  the research. During every visit, anthropomet-
ric measurements of  body weight and height were mea-
sured before (week 0) and after (week 12) the trial period. 
The primary endpoint was HbA1c (time frame, three 
months), whereas the secondary endpoints were plasma 
glucose concentration and plasma lipid profiles (choles-
terol, triglyceride, high- [HDL] and low- [LDL] density 
lipoprotein). Body mass index (BMI; time frame, three 
months) was measured at several visits during the study. 
Visit 1 was scheduled for information, screening, and in-
formed consent signature, visit 2 for randomization and 
first drug issue, and visit 3 was scheduled 12 weeks later. 
The outcomes were estimated at the time of  enrollment 
in the study and then after three months. The results of  
the inquiry then were compared at the end of  12 weeks 
of  study.
The assessment encompassed laboratory investigations, 
including FBG. The levels of  HbA1c were determined 
before the study and then at the end of  week 12. A 
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Dextrostix automatic biochemistry analyzer (Beck-
man-Coulter, Brea, CA, USA) was used to estimate the 
blood glucose levels through the glucose oxidase method. 
HbA1c, on the other hand, was estimated by an auto-
matic HbA1c apparatus (Bio-Rad Laboratories, Hercules, 
CA, USA).
Rejection and dropout
Patients were rejected if  they were inconsistent with the 
inclusion criteria. Those who had poor compliance were 
dropped from the study, as well as individuals who suf-
fered immense adverse effect or who withdrew from the 
study at their discretion. Statistical analysis was conducted 
in accordance with the intention to treat (ITT) analysis.
Statistical analysis
The data were analyzed with the Statistical Program SPSS 
(Statistical Package for Social Science; SPSS, Inc., Chicago, 
IL, USA), version 20. Descriptive statistics comprised the 
mean and standard deviation (SD). Post- and pre-treat-
ment data were compared using the paired t-test. Investi-
gational groups were compared regarding the quantitative 
variables using Student’s t-test for independent samples 
as normal distribution ensured. A probability value (P 
value) <0.05 was considered significant with 95% confi-
dence interval (CI). Biostatistics was performed accord-
ing to ITT analysis. Every procedure in the study used 




A total of  12 patients were recruited to the study, with 
a disease course of  4.8 ± 2.1 years.  Six patients (mean 
age, 50.8 ± 11.3 years) randomized to receive fenugreek 
(group 1) and 6 (mean age, 51.5 ± 10.1 years) randomized 
to receive glibenclamide (group 2; P = 0.92). One patient 
was withdrawn from group 1, whereas 2 were withdrawn 
from group 2 due to changing medication or personal 
problems. All participants were followed until the end of  
the study, and their data were included in the statistical 
analysis. BMI was 28.2 ± 2.1 in group 1 and 27.4 ± 2.2 in 
group 2. There was no significant difference between the 
groups regarding age or BMI (P > 0.05; Table 1).
Table 1: Characteristics of the study patients receiving fenugreek  
or glibenclamide at baseline 
  Fenugreek Glibenclamide P value 
Age 50.8 ± 11.3 51.5 ± 10.1 0.92 
Body weight (kg) 81.3 ± 7.1 80.9 ± 7.5 0.94 
BMI 
Body weight (kg)/height (m2) 28.2 ± 2.1 27.4 ± 2.2 0.6 
  
  
At the end of  the study, the mean patient weight was 
78.78 ± 8.23 and 80.60 ± 7.3 kg in the groups 1 and 2, 
respectively, whereas the BMI was 27.32 ± 2.12 and 27.3 
± 1.31, respectively, which was not statistically significant 
compared with the baseline values (P > 0.05). 
There was no significant statistical difference between the 
two groups concerning the following biochemical and 
hematological reactions at baseline (Table 2): Aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
creatinine, uric acid, blood urea nitrogen (BUN), alkaline 
phosphatase, bilirubin, hemoglobin, hematocrit, red cell 
count, mean corpuscular volume (MCV), mean corpus-
cular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), leukocyte count, basophils, eo-
sinophils, lymphocytes, monocytes, and platelet count.
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Table 2: Biochemical and hematological investigations of the study patients receiving 
fenugreek or glibenclamide at baseline 
  Fenugreek (n = 5) Glibenclamide (n = 4) P value 
AST (U/L) 17.8 ± 2.94 17.75 ± 1.7 0.21 
ALT (U/L) 24.8 ± 5.4 24.75 ± 2.98 0.98 
Alkaline phosphatase (U/L) 63.6 ± 14.9 76.2 ± 16.74 0.27 
Creatinine (mg/dL) 0.72 ± 0.14 0.67 ± 0.0.28 0.76 
BUN (mg/dL) 14.20 ± 3.34 13.25 ± 7.27 0.80 
Uric acid (mg/dL) 5.52 ± 1.25 5.05 ± 1.66 0.64 
Bilirubin (mg/dL) 0.42 ± 0.16 0.35 ± 0.10 0.48 
Hemoglobin (mg/dL) 11.77 ± 6.47 13.26 ± 1.41 0.71 
Hematocrit (%) 48.20 ± 6.01 41.55 ± 3.86 0.09 
Red cell count (mil/cmm) 5.44 ± 0.74 4.70 ± 0.46 0.12 
MCV (fL) 88.74 ± 3.93 88.57 ± 6.30 0.96 
MCH (Pg) 27.68 ± 1.29 27.87 ± 2.4 0.88 
MCHC (gm/dL) 31.20 ± 0.62 31.47 ± 0.45 0.48 
Leukocyte count (cmm) 8480.18 ± 2684.46 5925.00 ± 693.27 0.13 
Basophils (0–2%) 0.00 ± 0.00 0.00 ± 0.00 NS 
Eosinophils (0–6%) 1.80 ± 0.44 2.00 ± 0.00 0.40 
Lymphocytes (15–45%) 35.40 ± 9.78 38.25 ± 8.05 0.65 
Monocytes (4–9%) 2.00 ± 0.00 2.25 ± 0.50 0.29 
Platelet count (cmm) 311.60 ± 76.88 377.50 ± 107.45 0.31 
Values were mean ± SD, significant level was considered at P < 0.05. Patients in both groups were on metformin. 
AST: Aspartate aminotransferase, ALT : alanine aminotransferase, BUN: blood urea nitrogen, MCV: mean 
corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration.   
The primary outcome measures were FBG level, insulin 
level HbA1c, and homeostatic model assessment for insu-
lin resistance (HOMA-IR), whereas secondary outcome 
measures were lipid profile (HDL, LDL, triglycerides, to-
tal cholesterol, and HDL/LDL ratio). As shown in Table 
3, all parameters remained as before except for fasting 
insulin level, which showed an increase in HOMA-IR in 
group 1 from 6.98 ± 1.78 to 9.62 ± 3.16 μU/mL (95% 
CI, 0.10–5.17; P = 0.04) and an increase in the HDL/
LDL ratio in group 1 from 0.38 ± 0.08 to 0.50 ± 0.22 
(95% CI, 0.243–0.78; P = 0.006).
Administration of  fenugreek for three months in addi-
tion to conventional therapy decreased the FBG, although 
this decrease was not significant. Furthermore, HbA1c 
decreased but did not reach normal values (6.2). On the 
other hand, administration of  glibenclamide in addition 
to the conventional therapy metformin for three months 
non-significantly decreased the FBG, HOMA-IR, and 
HbA1c.
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Table 3: The effect of fenugreek and glibenclamide on blood glucose and lipid profile 
before and after treatment. 
  Fenugreek (2 g/dL) (n = 5) 
Glibenclamide (5 mg OD) 
(n = 4) 


































































































































Values were mean ± SD, significant level was considered at 0.05. FBG: fasting blood glucose,  HOMA-IR: 
homeostatic model assessment for insulin resistance, HbA1c: hemoglobin A1c, HDL: high density lipoprotein, 
LDL: low density lipoprotein. 
Next, the effects of  fenugreek on controlling blood 
glucose and lipid were compared with those of  gliben-
clamide. Table 4 showed that there was a non-significant 
lowering of  FBG in group 2 compared with group 1. 
Moreover, there was an insignificant difference between 
the groups with respect to fasting insulin release.
On the other hand, insulin resistance decreased more sig-
nificantly in group 2 than in group 1 (HOMA-IR, 2.23 ± 
0.22 vs. 3.53 ± 2.23, respectively; 95% CI, 0.78–3.48; P = 
0.007). Furthermore, compared with fenugreek, gliben-
clamide significantly lowered the HbA1c (95% CI, 0.05–
3.96; P = 0.04) and triglyceride (134.00 ± 17.56 vs. 204.00 
± 51.02 mg/dL; 95% CI, 6.15–133.84, P = 0.036) values.
Safety Parameters Comparison
No significant change was noted before and after therapy 
in ALT, AST, BUN, and creatinine levels in both groups 
(P > 0.05) (Supplement 1).
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Table 4: Comparison between fenugreek and glibenclamide on blood glucose control and 




Fenugreek (2 g/dL) 
(n = 5) 
Glibenclamide (5 mg OD) 
(n = 4) 
95% CI 
(P-value) 
























































0.4) 0.38 ± 0.22 0.51 ± 0.17 
−0.456–0.20 
(0.394) 
Values were mean of the absolute result numbers ± SD, significant level was considered <0.05, 95% CI. FBG: 
fasting blood glucose,  HOMA-IR: homeostatic model assessment for insulin resistance, HbA1c: hemoglobin A1c, 
HDL: high density lipoprotein, LDL: low density lipoprotein. 
Adverse reaction
No hepatic or renal adverse effects were noted with 
any participant in the course of  the study. One patient 
in group 1 suffered from hypoglycemia during the treat-
ment period. No adverse effects were noted at the end 
of  the research, and all participants proceeded with the 
study to its conclusion with no withdrawal.
Discussion
In the present study, fenugreek was provided to patients 
with type 2 DM as adjuvant therapy in addition to the con-
ventional antidiabetic medications. Fenugreek decreased 
the fasting blood sugar, although the reduction was not 
significant compared with glibenclamide. More interest-
ingly, our results revealed a significant increase in fasting 
insulin level as well as an increase in the HDL/LDL ratio 
after administration of  fenugreek for three months. Al-
though it is not significant, fenugreek decreased the HO-
MA-IR, HbA1c, LDL, and triglyceride levels.
Consistent with our results, Sharma et al.10 and Xue et al.8 
showed a steady decrease in triglycerides and LDL during 
a 24-week study period, with an in increase in HDL cho-
lesterol. In our study, reducing the activity of  LDL and 
increasing HDL and HDL/LDL indicated that the po-
tential beneficial effect of  fenugreek in preventing ath-
erosclerosis and hyperlipidemia in patients with diabetes. 
However, more animal experiments, and larger clinical 
trials need to be done to confirm this observation.
 
Consistent with our study, Gupta et al.11 showed a non-
significant difference between fenugreek and placebo 
groups regarding FBG, whereas fasting insulin release in-
creased with an increase in insulin sensitivity as showed 
by HOMA-IR; serum triglycerides decreased, and HDL 
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cholesterol increased significantly after 2 months. Mitra 
and Bhattacharya12 showed that fenugreek at higher doses 
decreased blood glucose and triglyceride levels and LDL 
and HDL cholesterol. Lu et al.13 concluded that fenugreek 
combined with sulfonylureas could lower the blood glu-
cose level and ameliorate the clinical symptoms for the 
treatment of  DM, and the therapy was relatively safe. In 
line with the present results, Kassaian et al.14 showed a 
decrease in FBS and triglycerides in 24 patients with type 
2 DM placed on 10 g/day powdered fenugreek seeds 
mixed with yogurt or soaked in hot water for 8 weeks. In 
this study, glibenclamide in adjuvant with sulfonylureas 
significantly decreased HbA1c compared to fenugreek. 
HbA1c is the index of  long-term glucose control. It has 
been shown that the 1% reduction in HbA1c in diabetic 
patients decreased the risk of  microvascular complica-
tions by 37% {Stratton, 2000 #1362}. Thus, our results 
indicate that glibenclamide could be more beneficial in 
preventing long-term DM complications. However, one 
must notice that the baseline HbA1c in glibenclamide 
group in this study has a lower level of  HbA1c than fen-
ugreek group. 
 
The importance of  our study is that it sheds some light 
on the mechanism of  fenugreek on lowering blood glu-
cose. Fenugreek significantly lowered serum insulin and 
HOMA-IR in patients on fenugreek for three months. 
Type 2 DM occurs due to insufficient supply of  insulin 
from dysfunctional beta cells of  the Islets of  Langerhans 
of  the pancreas. Insulin resistance occurs when the body 
cells fail to respond appropriately to the effects of  in-
sulin15,16. Moreover, another mechanism of  fenugreek in 
lowering blood glucose could be related to the high fiber 
content of  fenugreek, either the total or mucilaginous 
fibers12. Another reason for the blood glucose lowering 
effect may be related to the delayed gastric emptying that 
inhibits glucose transport and inhibits its absorption. 
Also, gastric emptying may be related to the galactoman-
nan content of  fenugreek that forms gel and also is re-
sponsible for lowering body weight.
 
Conclusion
The incidence of  diabetes has been on the rise proba-
bly due to lifestyle changes that encourage sedentary life-
styles, lack of  exercise, and aging. Herbal medication has 
gained much relevance in the recent past as an alternative 
therapy. Our study was conducted to determine the hy-
poglycemic and hypolipidemic impacts of  fenugreek seed 
on patients with type 2 DM. A 2 g/day dose of  fenugreek 
for 12 weeks caused a significant increase in serum insu-
lin and HDL/LDL ratio. Fenugreek did not cause any 
notable adverse effects on hepatic and renal functions 
throughout the study. Thus, fenugreek could be a benefi-
cial adjuvant therapy in the glycemic control of  patients 
with type 2 DM. However, larger scale clinical trials are 
needed to confirm those results.
Study limitations
The main limitation in the present study was the small 
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